Skip to content
2000
Volume 32, Issue 9
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

Introduction

Glioblastoma Multiforme (GBM) is a highly aggressive and fatal brain malignancy, with Temozolomide (TMZ) serving as the first-line chemotherapeutic treatment. However, over 50% of patients do not respond to TMZ, and the underlying mechanisms remain unclear. This study utilized the GeCKO library to identify novel genes involved in TMZ resistance and to explore their functions.

Methods

Loss-of-function genes related to TMZ resistance in GBM cells were identified using the GeCKO library and Next-Generation Sequencing (NGS), validated by qPCR and CCK-8 assays. CD99L2 function was assessed through proliferation, migration, and EdU assays in U251 and U87 cells. Tumor samples from 55 stage IV GBM patients were analyzed to explore the correlation between CD99L2 expression and Progression-Free Survival (PFS).

Results

GeCKO library screening identified seven genes associated with TMZ resistance. After validation, CD99L2 was confirmed as a key contributor to TMZ resistance. Knockdown of CD99L2 increased the IC of U251 and U87 cells by 1.39- and 1.54-fold, respectively. Conversely, CD99L2 overexpression reduced the IC by 0.52- and 0.58-fold. CD99L2 knockdown also promoted tumor proliferation and aggressiveness. Additionally, higher CD99L2 expression was associated with longer PFS in GBM patients (median PFS: 7.87 months 2.7 months, =0.0003).

Discussion

The functions of CD99L2 remain poorly understood. A few studies have reported that CD99L2 may serve as an adhesion molecule modulating inflammatory responses. One study has shown that CD99L2 is highly expressed in the brain and affects neuronal excitability. These findings suggest that CD99L2 may play a positive role in the body’s defense against glioma.

Conclusion

This study demonstrated that CD99L2 knockdown promotes TMZ resistance and tumorigenesis in GBM, suggesting its potential as a novel biomarker for TMZ resistance.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpd/10.2174/0113816128386002250701113848
2025-07-18
2026-02-24

  • From This Site

    /content/journals/cpd/10.2174/0113816128386002250701113848
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. BeierD. SchulzJ.B. BeierC.P. Chemoresistance of glioblastoma cancer stem cells - much more complex than expected.Mol. Cancer201110112810.1186/1476‑4598‑10‑128 21988793
     [Google Scholar]
  2. AlexanderB.M. CloughesyT.F. Adult Glioblastoma.J. Clin. Oncol.201735212402240910.1200/JCO.2017.73.0119 28640706
     [Google Scholar]
  3. OmuroA. DeAngelisL.M. Glioblastoma and other malignant gliomas: A clinical review.JAMA2013310171842185010.1001/jama.2013.280319 24193082
     [Google Scholar]
  4. LouisD.N. PerryA. ReifenbergerG. The 2016 world health organization classification of tumors of the central nervous system: A summary.Acta Neuropathol.2016131680382010.1007/s00401‑016‑1545‑1 27157931
     [Google Scholar]
  5. MillerK.D. NogueiraL. MariottoA.B. Cancer treatment and survivorship statistics, 2019.CA Cancer J. Clin.201969536338510.3322/caac.21565 31184787
     [Google Scholar]
  6. HotchkissK.M. SampsonJ.H. Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor.J. Neurooncol.20211511556210.1007/s11060‑020‑03598‑2 32813186
     [Google Scholar]
  7. D’AlessioA. ProiettiG. SicaG. ScicchitanoB.M. Pathological and molecular features of glioblastoma and its peritumoral tissue.Cancers201911446910.3390/cancers11040469 30987226
     [Google Scholar]
  8. Iturrioz-RodríguezN. SampronN. MatheuA. Current advances in temozolomide encapsulation for the enhancement of glioblastoma treatment.Theranostics20231392734275610.7150/thno.82005 37284445
     [Google Scholar]
  9. BocangelD.B. FinkelsteinS. ScholdS.C. BhakatK.K. MitraS. KokkinakisD.M. Multifaceted resistance of gliomas to temozolomide.Clin. Cancer Res.20028827252734 12171906
     [Google Scholar]
  10. Hombach-KlonischS. MehrpourM. ShojaeiS. Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis, autophagy, and unfolded protein response.Pharmacol. Ther.2018184134110.1016/j.pharmthera.2017.10.017 29080702
     [Google Scholar]
  11. AldapeK. ZadehG. MansouriS. ReifenbergerG. von DeimlingA. Glioblastoma: pathology, molecular mechanisms and markers.Acta Neuropathol.2015129682984810.1007/s00401‑015‑1432‑1 25943888
     [Google Scholar]
  12. LangF. LiuY. ChouF.J. YangC. Genotoxic therapy and resistance mechanism in gliomas.Pharmacol. Ther.202122810792210.1016/j.pharmthera.2021.107922 34171339
     [Google Scholar]
  13. LinK. GuebleS.E. SundaramR.K. HusemanE.D. BindraR.S. HerzonS.B. Mechanism-based design of agents that selectively target drug-resistant glioma.Science2022377660550251110.1126/science.abn7570 35901163
     [Google Scholar]
  14. ZhouJ. TongF. ZhaoJ. Identification of the E2F1-RAD51AP1 axis as a key factor in MGMT-methylated GBM TMZ resistance.Cancer Biol. Med.202320538540010.20892/j.issn.2095‑3941.2023.0011 37283490
     [Google Scholar]
  15. OldriniB. Vaquero-SigueroN. MuQ. MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas.Nat. Commun.2020111388310.1038/s41467‑020‑17717‑0 32753598
     [Google Scholar]
  16. AbeH. NatsumedaM. OkadaM. MGMT expression contributes to temozolomide resistance in H3K27M-mutant diffuse midline gliomas.Front. Oncol.20209156810.3389/fonc.2019.01568 32039031
     [Google Scholar]
  17. ZhangK. WangX. ZhouB. ZhangL. The prognostic value of MGMT promoter methylation in Glioblastoma multiforme: A meta-analysis.Fam. Cancer201312344945810.1007/s10689‑013‑9607‑1 23397067
     [Google Scholar]
  18. YiG. HuangG. GuoM. Acquired temozolomide resistance in MGMT-deficient glioblastoma cells is associated with regulation of DNA repair by DHC2.Brain201914282352236610.1093/brain/awz202 31347685
     [Google Scholar]
  19. CongL. RanF.A. CoxD. Multiplex genome engineering using CRISPR/Cas systems.Science2013339612181982310.1126/science.1231143 23287718
     [Google Scholar]
  20. MaliP. YangL. EsveltK.M. RNA-guided human genome engineering via Cas9.Science2013339612182382610.1126/science.1232033 23287722
     [Google Scholar]
  21. HannaR.E. DoenchJ.G. Design and analysis of CRISPR-Cas experiments.Nat. Biotechnol.202038781382310.1038/s41587‑020‑0490‑7 32284587
     [Google Scholar]
  22. ShalemO. SanjanaN.E. HartenianE. Genome-scale CRISPR-Cas9 knockout screening in human cells.Science20143436166848710.1126/science.1247005 24336571
     [Google Scholar]
  23. WeiL. LeeD. LawC.T. Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC.Nat. Commun.2019101468110.1038/s41467‑019‑12606‑7 31615983
     [Google Scholar]
  24. CaoJ. WeiJ. YangP. Genome-scale CRISPR-Cas9 knockout screening in gastrointestinal stromal tumor with Imatinib resistance.Mol. Cancer201817112110.1186/s12943‑018‑0865‑2 30103756
     [Google Scholar]
  25. MacLeodG. BozekD.A. RajakulendranN. Genome-wide CRISPR-Cas9 screens expose genetic vulnerabilities and mechanisms of temozolomide sensitivity in glioblastoma stem cells.Cell Rep.2019273971986.e910.1016/j.celrep.2019.03.047 30995489
     [Google Scholar]
  26. OuyangQ. LiuY. TanJ. Loss of ZNF587B and SULF1 contributed to cisplatin resistance in ovarian cancer cell lines based on Genome-scale CRISPR/Cas9 screening.Am. J. Cancer Res.201995988 31218106
     [Google Scholar]
  27. BixelM.G. PetriB. KhandogaA.G. A CD99-related antigen on endothelial cells mediates neutrophil but not lymphocyte extravasation in vivo.Blood2007109125327533610.1182/blood‑2006‑08‑043109 17344467
     [Google Scholar]
  28. NamG. LeeY.K. LeeH.Y. Interaction of CD99 with its paralog CD99L2 positively regulates CD99L2 trafficking to cell surfaces.J. Immunol.2013191115730574210.4049/jimmunol.1203062 24133166
     [Google Scholar]
  29. RamosP.S. SajuthiS. LangefeldC.D. WalkerS.J. Immune function genes CD99L2, JARID2 and TPO show association with autism spectrum disorder.Mol. Autism201231410.1186/2040‑2392‑3‑4 22681640
     [Google Scholar]
  30. SuhY.H. ShinY.K. KookM.C. Cloning, genomic organization, alternative transcripts and expression analysis of CD99L2, a novel paralog of human CD99, and identification of evolutionary conserved motifs.Gene2003307637610.1016/S0378‑1119(03)00401‑3 12706889
     [Google Scholar]
  31. BixelM.G. LiH. PetriB. CD99 and CD99L2 act at the same site as, but independently of, PECAM-1 during leukocyte diapedesis.Blood201011671172118410.1182/blood‑2009‑12‑256388 20479283
     [Google Scholar]
  32. SamusM. SeeligeR. SchäferK. SorokinL. VestweberD. CD99L2 deficiency inhibits leukocyte entry into the central nervous system and ameliorates neuroinflammation.J. Leukoc. Biol.2018104478779710.1002/JLB.1A0617‑228R 29791026
     [Google Scholar]
  33. LiuF. ZhangG. LiuF. Effect of shRNA targeting mouse CD99L2 gene in a murine B cell lymphoma in vitro and in vivo.Oncol. Rep.20132941405141410.3892/or.2013.2244 23338758
     [Google Scholar]
  34. ZengJ. ZhangL. HuangL. MAZ promotes thyroid cancer progression by driving transcriptional reprogram and enhancing ERK1/2 activation.Cancer Lett.202460221720110.1016/j.canlet.2024.217201 39197582
     [Google Scholar]
  35. ShenY. ZhangN. ChaiJ. CircPDIA4 induces gastric cancer progression by promoting ERK1/2 activation and enhancing biogenesis of oncogenic circRNAs.Cancer Res.202383453855210.1158/0008‑5472.CAN‑22‑1923 36562654
     [Google Scholar]
  36. FlintA.C. MitchellD.K. AngusS.P. Combined CDK4/6 and ERK1/2 inhibition enhances antitumor activity in NF1-associated plexiform neurofibroma.Clin. Cancer Res.202329173438345610.1158/1078‑0432.CCR‑22‑2854 37406085
     [Google Scholar]
  37. XuM.H. ZhengY.M. LiangB.G. Deubiquitination of CIB1 by USP14 promotes lenvatinib resistance via the PAK1-ERK1/2 axis in hepatocellular carcinoma.Int. J. Biol. Sci.20242093269328410.7150/ijbs.96031 38993552
     [Google Scholar]
  38. KimY. JungK.Y. KimY.H. Inhibition of SIRT7 overcomes sorafenib acquired resistance by suppressing ERK1/2 phosphorylation via the DDX3X-mediated NLRP3 inflammasome in hepatocellular carcinoma.Drug Resist. Updat.20247310105410.1016/j.drup.2024.101054 38277756
     [Google Scholar]
  39. WeiY. LuC. ZhouP. EIF4A3-induced circular RNA ASAP1 promotes tumorigenesis and temozolomide resistance of glioblastoma via NRAS/MEK1/ERK1–2 signaling.Neuro-oncol.202123461162410.1093/neuonc/noaa214 32926734
     [Google Scholar]
  40. HeZ. ChengM. HuJ. miR-1297 sensitizes glioma cells to temozolomide (TMZ) treatment through targeting adrenomedullin (ADM).J. Transl. Med.202220144310.1186/s12967‑022‑03647‑6 36183123
     [Google Scholar]
/content/journals/cpd/10.2174/0113816128386002250701113848
Loading
Loss of CD99L2 Contributed to Temozolomide Resistance and Glioblastoma Tumorigenesis Based on Genome-scale CRISPR/Cas9 Screening
Curr. Pharm. Des. 32, 696 (2026); https://doi.org/10.2174/0113816128386002250701113848
/content/journals/cpd/10.2174/0113816128386002250701113848
/content/journals/cpd/10.2174/0113816128386002250701113848
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): CD99L2; CRISPR/Cas9; glioblastoma multiforme; temozolomide resistance; tumorigenesis

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test